Neuroscience

Collaborate with our dedicated team of experts, offering strategic leadership and tailored support for your Clinical Neuroscience disease clinical trials.

Emmes' Neuroscience team harness more than **20 years** of clinical development expertise, spanning work in both public and private sectors. We provide full-service support across all phases of clinical development. Emmes has deep knowledge and expertise in neuroscience clinical research across many indications and all phases, making our services best placed to advance your neuroscience research program.

Our client collaborations have been enhancing clinical practice and treatment of neurological and psychiatric disorders for decades, positively impacting human health, public policy and the testing of innovative therapeutic solutions.

Modernizing clinical research with tech & AI

At Emmes we are modernizing and automating clinical research across the full spectrum of clinical trial activities to operate faster, more efficiently, and with higher quality. We are the industry's first native digital and AI specialty CRO built on a proprietary technology and AI platform.

Services Offerings

- Protocol Development
- Emmes Endpoint Solutions
- Clinical Trial Management
- Site Management and Monitoring
- Data Management
- Pharmacovigilance
- Quality Assurance
- Biostatistics & Bioinformatics
- Global Regulatory Affairs

What sets us apart?

Benefits of our services

Partnership with National Institutes of Health- Including The National Institute of Mental Health (NIMH), The National Institute of Neurological Disorders and Stroke (NINDS) and The National Institute on Drug Abuse (NIDA) for more than 20 years.

Breadth of expertise- spans multiple domains including multi- site psychedelic research, substance use disorders, traumatic brain injury, epilepsy, neurodegenerative indications, and rare neuromuscular (e.g., Duchenne Muscular Dystropy) and neurodevelopmental (e.g., Angelman Syndrome, Rett Syndrome) indications, among others.

Patient advocacy connections- Harnessing Patient Advocacy Group (PAG) relationships to support sponsors with recruitment and retention goals as well as regulatory strategy particularly in rare indications.

Novel endpoint development- Emmes Endpoint Solutions offer novel homebased patient and caregiver-focused outcome measure solutions, e.g. the Duchenne Video Assessment Tool, the first Duchenne Muscular Dystrophy (DMD) outcome accepted into FDA's COA Qualification Program.

Highlights Include

Exploring endpoint selection in a complex therapeutic area- provided 10 years of full-scope CRO support for a large DoD-sponsored mild TBI/PTSD clinical research program in US active-duty military and veterans including the Brain Injury and Mechanisms of Action (BIMA) and NORMAL studies. At the time of study execution, represented the largest and most comprehensive study of those with sequelae following mTBI and complementary normative cohort. Leading to 25+ co-authored publications and 30+ conference presentations.

NIDA partnership- NIDA ADAPT-2 Study- Emmes demonstrated that treatment with the combination of extended-release injectable naltrexone and daily oral extended-release bupropion helped adults with methamphetamine use disorder (MUD), which is important because there are currently no FDA-approved medications for MUD treatment.

A leading CRO in the psychedelic renaissance- providing support for rigorous multi-site psychedelic trials since 2017 with experience in major depressive disorder, alcohol use disorder, migraine, and rare headache disorders. Emmes' successful delivery of a large multi-site Phase 2 clinical trial for Major Depressive Disorder led to positive clinical trial results published in JAMA, becoming one of the most viewed JAMA articles of 2023.

For additional information on our Neuroscience services, please visit www.emmes.com

Key Statistics

180+
Studies

75
Studies in substance use disorders

50+
Indications

320+
Peer-reviewed publications

20+
Years experience in neuroscience

Emmes